Matthew S. Scarano

Associate
Full contact info

Experience

Everbridge Enters Into Definitive Agreement to Be Acquired by Thoma Bravo for $1.8 Billion

March 1, 2024

Cooley advised Everbridge, a global leader in critical event management and national public warning solutions, on its definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valuing Everbridge at approximately $1.8 billion.

Read more

Related contacts

Jamie Leigh
Partner, San Francisco
Kevin Cooper
Partner, New York
Polina A. Demina
Associate, New York
C. Thomas Hopkins
Partner, Los Angeles Santa Monica
Brad Goldberg
Partner, New York
Mischi a Marca
Partner, San Francisco
Caitlin Courtney
Partner, Palo Alto
Michael Egan
Partner, Washington, DC
David Fletcher
Partner, Washington, DC
Annie Froehlich
Partner, Washington, DC
Patrick Flanagan
Partner, New York
Stephanie Gentile
Partner, New York
Christopher Kimball
Partner, Washington, DC
Barbara Mirza
Partner, Los Angeles Santa Monica
Howard Morse
Partner, Washington, DC
Miriam Petrillo
Partner, Chicago
Jason Savich
Partner, San Francisco
Dillon Martinson
Special Counsel, Washington, DC
Stella Sarma
Special Counsel, Brussels
Grant Schweikert
Special Counsel, Washington, DC
Umer Chaudhry
Associate, Washington, DC
Katherine Denby
Associate, Washington, DC
Alexander Ellebracht
Associate, Palo Alto
Athina Gaki
Associate, Brussels
Carly E. Gibbons
Associate, Chicago
Daniel Han
Associate, New York
Gary Warren Hunt III
Associate, Washington, DC
Alexandra Leavy
Associate, New York
Jeewon Lee
Associate, New York
Morgan Lloyd
Associate, New York
Joe Mandry
Associate, San Diego
Matthew S. Scarano
Associate, San Diego
Ben Sweeney
Associate, Los Angeles Downtown
Mickeala Tu
Associate, Palo Alto
Genevieve Lim Urban
Associate, Seattle
Rubin Waranch
Associate, Colorado
Lois NaYeon Yoo
Associate, New York

Related Practices & Industries

Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179

February 14, 2024

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Rama Padmanabhan
Partner, San Diego
Rajdeep Roger Bains
Associate, San Diego
Jason Savich
Partner, San Francisco
Lila Hope
Partner, Palo Alto
Michael Klein
Partner, New York
Michelle Garcia Schulman
Partner, Reston
Matthew S. Scarano
Associate, San Diego
Jameson Davis
Associate, Boston
Kaiting Yang
Associate, Hong Kong
Ross Eberly
Partner, Los Angeles Santa Monica
Jeffrey J. Tolin
Partner, New York
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Robert Eisenbach
Of Counsel, San Francisco
Rena Kaminsky
Special Counsel, Palo Alto
Olya Antle
Associate, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Yoni Horn
Associate, Los Angeles Santa Monica
Lunga Su
Associate, Shanghai
Yiying Wang
Associate, Shanghai

Related Practices & Industries

Autolus Announces Strategic Collaboration With BioNTech, $350 Million Underwritten Offering

February 8, 2024

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Stephanie Parker Palmer
Special Counsel, Reston
Carly Robinson
Associate, Reston
Joe Sandys
Associate, London
Alexandra Paterson
Associate, London
Christian Plaza
Partner, Reston
Courtney Thorne
Partner, Boston
Brian Leaf
Partner, Reston
William DuVal
Associate, Reston
Trevor Bossi
Associate, Boston
Tyler Day
Associate, Reston
Claire Keast-Butler
Partner, London
Mandy Ching
Associate, London
Natasha Kaye
Partner, London
Megan Browdie
Partner, Washington, DC
Ann Bevitt
Partner, London
John Clark
Partner, London
Kevin King
Partner, Washington, DC
Matthew Pavao
Partner, Boston
Barbara Borden
Partner, San Diego
David Wilson
Partner, London
Christine Graham
Special Counsel, London
Rebecca Ross
Special Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Jacqueline Moore
Special Counsel, London
Jack Jones
Associate, London
Rubin Waranch
Associate, Colorado
Jessica Cande
Associate, Boston
Anna Caro
Associate, London
Jan Lang
Associate, Brussels
Eerik Kukebal
Associate, London
Jordan Verrilli
Associate, New York
Matthew S. Scarano
Associate, San Diego
Margaux Arntson
Associate

Related Practices & Industries

Blue Owl Capital Invests up to $1.05 Billion in BridgeBio Pharma

January 17, 2024

Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Michael Tollini
Partner, Washington, DC
Addison Pierce
Associate, Chicago
Matt Kong
Associate, San Francisco
Xander Lee
Partner, Los Angeles Santa Monica
Geoffrey Spolyar
Partner, Boston
Jon Cousin
Partner, Washington, DC
Steve Flores
Partner, Chicago
Phil Mitchell
Partner, New York
Michael Egan
Partner, Washington, DC
Jeffrey J. Tolin
Partner, New York
Michael Klein
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Susan Piascik Christoff
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Cathy Hershcopf
Senior Counsel, New York
Stevie Yu
Associate, New York
Yichao Zhang
Associate, New York
Rodrigo Huerta
Associate, Chicago
Jackson Alldredge
Associate, Colorado
Amanda Pacheco
Associate, Palo Alto
Celine Koh
Associate, Palo Alto
Jameson Davis
Associate, Boston
Allison Kutner
Associate, New York
Matthew S. Scarano
Associate, San Diego
Xueqing Li
Associate, San Francisco
Mor Agam
Associate, New York
Miriam Peguero Medrano
Associate, Chicago
Sam Rabuck
Associate, Chicago
Chris Rhem
Paralegal Specialist, San Francisco
Veronica Cortes
Paralegal Specialist, New York
Jennifer Fitzpatrick
Paralegal Specialist, Washington, DC
Jason Minio
Paralegal Specialist, Boston
Jeffery Wyzykowski
Patent Agent, Washington, DC

Related Practices & Industries

MannKind Announces up to $200 Million Royalty Purchase Agreement With Sagard Healthcare

January 2, 2024

Cooley advised MannKind, a company focusing on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases, on the sale of a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare for up to $200 million.

Read more

Related contacts

Matt Browne
Partner, San Diego
Amy Hallman Rice
Special Counsel, San Diego
Pitrina Gilger
Associate, San Diego
Amanda Pacheco
Associate, Palo Alto
Mischi a Marca
Partner, San Francisco
Matthew S. Scarano
Associate, San Diego
Asa Henin
Special Counsel, San Diego
Michelle Hunt
Associate
Chris Rhem
Paralegal Specialist, San Francisco

Related Practices & Industries

View more

Admissions and credentials

California

New York